| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2022 | 605.39% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 04/04/2022 | 605.39% | Jefferies | $29 → $17 | Maintains | Buy |
| 04/13/2021 | 1310.79% | Evercore ISI Group | → $34 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 1103.32% | Jefferies | → $29 | Initiates Coverage On | → Buy |
| 04/13/2021 | 937.34% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
Finch Therapeutics Group Questions & Answers
The latest price target for Finch Therapeutics Group (NASDAQ: FNCH) was reported by HC Wainwright & Co. on August 9, 2022. The analyst firm set a price target for $17.00 expecting FNCH to rise to within 12 months (a possible 605.39% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Finch Therapeutics Group (NASDAQ: FNCH) was provided by HC Wainwright & Co., and Finch Therapeutics Group initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Finch Therapeutics Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Finch Therapeutics Group was filed on August 9, 2022 so you should expect the next rating to be made available sometime around August 9, 2023.
While ratings are subjective and will change, the latest Finch Therapeutics Group (FNCH) rating was a initiated with a price target of $0.00 to $17.00. The current price Finch Therapeutics Group (FNCH) is trading at is $2.41, which is within the analyst's predicted range.